the urine (preferably 100% of unchanged material) will give valuable information about possible metabolism or excretion by other routes or inactivation by binding. Very occasionally an antibiotic is found which appears to have little or no means of elimination. A new polypeptide antibiotic, highly active against staphylococci resistant to many other antibiotics, was found recently which, upon injection, circulated for days on end (P W Muggleton & W F J Cuthbertson, personal communication). Protection could be obtained in mice when a challenge dose of staphylococci was preceded by a single dose of the antibiotic given more than 24 hours previously. The accumulation and toxic effects which might occur if repeated doses of such an antibiotic were given led to its rejection.
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Toxicity testing
Regardless of how effective an antibiotic might be in protecting animals against an experimental infection, it cannot be used if it is likely to be toxic. Such is the armamentarium of antibiotics now available to the physician that very high standards of acceptability must be met. In progressing a compound which looks promisingly effective in vitro and in vivo, it is usual to do preliminary tests in two species to eliminate quickly any highly toxic substance and to look for any specific target organs as the sites of toxicity. Obviously, whether it will be safe to proceed further with the compound will depend partly on the size of the ratio between the maximum dose producing no toxic effect and the dose producing a therapeutic effect, as revealed by the previous protection tests in animals. If this therapeutic ratio appears favourable, then further tests for possible toxicity must be done to progress the compound for administration to man. Often this progression occurs in three stages, the first of which is to clear the compound for the administration of single or a few repeat doses to human volunteers for pharmacokinetic studies. If the results of these studies are no good, the compound is rejected and the use of further laboratory animals is avoided. If the results are satisfactory, the second stage of much more extensive toxicity testing is undertaken, sufficient to clear the compound for limited clinical trial in patients. At this stage if full teratology studies have not been done, women of childbearing potential would be excluded from the trials. If these pilot, limited trials are satisfactory, full teratological and embryopathological studies will be done, together with any special toxicological investigations that may be necessary, such as determination of sensitizing potential and mutagenicity.
Assuming all goes well and extended clinical trials indicate that we have an antibiotic worthy of introduction into medical use, i.e. the results indicate that it may do something new, better or more safely, still further animal testing may be required to satisfy the registration authoritiesthe requirements often differing from country to countrybefore a licence to sell the substance is given.
It would be impossible at present, or in the foreseeable future, to develop a new antibiotic without extensive animal testing. These experiments are costly and for this reason alone no antibiotic manufacturer would use animals unnecessarily. However, and more importantly, humane and ethical considerations dictate that neither unnecessary usage of animals nor suffering to those that are used would be countenanced.
Uses and limitations of primates in the evaluation of drug efficacy and safety A D Dayan MD FRCPath Wellcome Research Laboratories, Langley Court, Beckenham, Kent BR3 3BS In research and development of drugs for man and evaluation of their safety, it is striking how limited has been the contribution of experiments in nonhuman primates. The reasons for this have included discovery of appropriate physiological or pathological mechanisms on which to test compoundsfirst in more convenient laboratory animals, and often subsequently in 1", 1978 The Royal Society of Medicine 0 1 41-0768/78/0071-0691/$O 1.00/0 purely test-tube phenomena, e.g. enzyme reactions, and the scarcity, cost and general difficulty of work in primates. Assessment of safety, which requires determination of the full range both of desired effects and unwanted toxic actions, has also been done more commonly in nonprimates for similar reasons. The variable condition and disease burden of wild-caught animals, with the consequences of irregular response to drugs, and of potential hazards to man and other animals, have all discouraged use of primates in pharmaceutical research, and have led to much greater use of other mammals.
There are circumstances when only a primate can be used to evaluate the effect of a drug. This applies, for example, to viral infections that occur in a very restricted range of animals (e.g. hepatitis A in man and higher apes), and research into treatment of these disorders is possible only in certain types of primate. If it were necessary to study effects on metabolism of steroids of the human pattern, this would have to be done in a very restricted range of species; on present evidence a higher ape would be required, or the Common Marmoset (Callithrix jacchus; Shackleton & Mitchell 1975 ). Because of cross-reacting antigens, antihuman lymphocyte globulin can be assayed only in certain apes and macaques. Other very specialized abilities may be manifested only in primatese.g., certain aspects of intelligence, manual skill and social interactionsso they, too, could not be examined in other species; but modification by drugs of such higher functions is not yet a deliberate goal of much therapeutic research.
The majority of pharmacological and physiological mechanisms are common to most vertebrate species, so it is not surprising that many of the powerful drugs now available have been developed in conventional laboratory animals, such as the rat and rabbit (or from serendipitous observation in man). This argument is always in danger of becoming circular in view of the expense and practical difficulty of working with primates rather than rodents, but so far it is still generally valid.
To test the safety of a drug requires evaluation of its known pharmacodynamic actions after' a wide range of doses, as well as the broadest possible screen for the unexpected and often harmful 'toxic' effects. The former, as a direct extension of pharmacological studies, is not likely to be done in primates, because they so rarely exhibit responses of human type not elicitable in other animals. On the other hand it may sometimes be necessary to assess toxicity in primates if it is only in these species that the rate or route of metabolism of the parent compound and its degradation products are similar to man (Smith & Caldwell 1977) , and if there is good evidence that behaviour of the compound in other species is so different that their responses cannot be an adequate guide to the consequences of human treatment. It is important to realize that final evaluation of a drug can only be made in the species for which it is intended, and observations in man himself must form part of the assessment of therapeutic activity and safety of any drug in clinical use.
In the context of this symposium, the conclusion must be that primates are essential for very few types of research into drugs and their effects, and that they carry many disadvantages. They should be regarded, not with anthropocentric awe as 'little men', but like any other laboratory animal and, therefore, are to be employed with respect and caution, and then only if an alternative is not available and after considering their scarcity, hazards and true value. The appeal of possible alternatives and the effort put into finding them have become more pressing as realization has grown of the limitations of conventional laboratory primates. At the same time, better understanding has come of man as a laboratory animal, and recognition that clinical trial of a medicine requires as much assessment of toxicity as of efficacy (Dengler et al. 1977) .
